Calidi Biotherapeutics Inc (CLDI) FinancialsCLDIFinancialCalidi Biotherapeutics Inc

Evaluating the bottom line, Calidi Biotherapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -957.89%, provide a clear picture of how effectively CLDI converts its operational activities into shareholder value.

In the context of the broader market, CLDI competes directly with industry leaders such as PHGE and CRIS. With a market capitalization of $4.11M, it holds a significant position in the sector. When comparing efficiency, CLDI's gross margin of N/A stands against PHGE's N/A and CRIS's N/A. Such benchmarking helps identify whether Calidi Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

Calidi Biotherapeutics has reported a series of substantial net losses, with Q2 2026 showing a net income of -$4,160,000. The company has a negative PE ratio of -0.19188 and a forward PE of 0, indicating no earnings expectations in the near term. The current ratio is 1.68, which is acceptable but not strong enough to alleviate concerns about liquidity given the company's ongoing losses.